GlassScriptPhysician profile
Carolyne Thomas
NPI 1891473609
$1,009.88
in general payments reported to CMS, 2019-2025
23 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $138 · 2024: $542 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $203.11 | 2024-2025 | |
| Novo Nordisk INC | $101.86 | 2024-2025 | Rybelsus, Ozempic, Tresiba |
| Lilly USA, LLC | $96.58 | 2023-2025 | Mounjaro, Jardiance |
| Pfizer INC. | $65.36 | 2024-2025 | |
| Amgen INC. | $60.20 | 2024 | Otezla, Krystexxa, Repatha |
| Glaxosmithkline, LLC. | $51.98 | 2024-2025 | Shingrix, Arexvy |
| Eisai INC. | $44.07 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $43.40 | 2024-2025 | Farxiga, Airsupra |
| Seqirus USA INC | $39.54 | 2023-2024 | Flucelvax Quadrivalent, Fluad Quadrivalent, Flucelvax |
| Janssen Pharmaceuticals, INC | $38.28 | 2025 | Spravato |
| Boston Scientific Corporation | $36.38 | 2023 | Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $34.45 | 2023-2025 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $32.19 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.90 | 2023 | Xifaxan |
| Noven Therapeutics, LLC | $17.75 | 2024 | Xelstrym |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $17.22 | 2024 | Nexletol |
| Shield Therapeutics INC | $16.88 | 2025 | |
| Edwards Lifesciences Corporation | $16.82 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Axsome Therapeutics, INC. | $16.59 | 2024 | Auvelity |
| Exact Sciences Corporation | $15.99 | 2024 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $13.91 | 2024 | Flector, Licart, Tirosint |
| Gilead Sciences, INC. | $13.74 | 2023 | |
| Organon LLC | $13.68 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyne Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.